Skip to main content
Search

Asimov

2 related articles

Subscribe to updates
  1. Asimov

    Asimov signs licensing deal with LG Chem, putting its CHO Edge System into biologics cell line development

    Asimov has signed a licensing agreement under which South Korea-based LG Chem will in-license Asimov's CHO Edge System to support its biologics cell line development. The system includes the recently announced Chrysalis transposase and Kernel, Asimov's AI-driven genetic design software. The deal puts AI-assisted genetic design and cell line construction tools into the hands of a chemical company with an existing life sciences business, but the two sides did not disclose deal value, exclusivity or the specific development stage.

    Asimov
    CHO Edge systemAsimov–LG Chem licensing agreement
  2. Asimov

    Asimov and Sidewinder partner on cell line development: a 4-chain bispecific antibody reaches clonal titers above 10 g/L in a platform fed-batch process

    Asimov announced a cell line development partnership with Sidewinder Therapeutics and delivered a cell line for Sidewinder's 4-chain bispecific antibody candidate for solid tumors. Such complex molecules are hard to express, and Sidewinder needed both the required expression level and consistent product quality. Asimov ran the custom program with its CHO Edge system, which combines a GS knock-out CHO host, a hyperactive transposase, a genetic parts library and Kernel, its AI-driven genetic design software; in a platform fed-batch process the cell line achieved clonal titers of over 10 g/L.

    Asimov
    Cell line development partnershipCHO Edge system

You’re all caught up